Flumethasone (Flucort)

Flumethasone is a potent synthetic fluorinated glucocorticoid approved for veterinary use in cattle and horses, providing powerful anti-inflammatory and immunomodulatory effects for the management of inflammatory conditions affecting these species. This corticosteroid exhibits high glucocorticoid potency approximately 15 times that of cortisol (hydrocortisone), with negligible mineralocorticoid activity that minimizes sodium retention and potassium loss side effects. Flumethasone has established itself as a valuable therapeutic option in food animal and equine practice for conditions requiring potent, rapid-acting corticosteroid therapy.

The mechanism of action for flumethasone mirrors that of other synthetic glucocorticoids, involving binding to intracellular glucocorticoid receptors and subsequent modulation of gene transcription. This genomic mechanism produces comprehensive anti-inflammatory effects including suppression of inflammatory mediator production, stabilization of cellular and lysosomal membranes, reduction of capillary permeability and edema formation, inhibition of prostaglandin and leukotriene synthesis, and decreased migration of leukocytes to sites of inflammation. The potent anti-inflammatory activity of flumethasone allows therapeutic effects to be achieved at relatively low absolute doses.

Commercially available flumethasone formulations are typically provided as sterile injectable solutions suitable for intravenous, intramuscular, intra-articular, and intralesional administration routes. The water-soluble nature of these preparations provides rapid onset of action following parenteral administration, with peak effects occurring within hours of injection. The relatively short biological half-life of flumethasone compared to some depot corticosteroid formulations may be advantageous when shorter duration of effect is desired or when repeated dosing flexibility is important.

Regulatory approval for flumethasone in the United States includes specific indications in cattle and horses, with established withdrawal times for approved uses. The approved product labeling provides guidance on dosing, administration routes, and withdrawal requirements that support compliant use in food-producing animals. Extra-label applications require veterinary prescription under a valid VCPR with appropriate withdrawal time determination through FARAD consultation. The established regulatory framework and clinical experience with flumethasone support its continued role in food animal and equine veterinary practice.

The therapeutic indications for flumethasone in cattle encompass a range of inflammatory and metabolic conditions where potent glucocorticoid activity provides clinical benefit. Primary anti-inflammatory applications include acute musculoskeletal injuries, traumatic inflammation, post-surgical swelling, and severe inflammatory reactions affecting various body systems. The rapid onset and potent anti-inflammatory effects of flumethasone help control pain, swelling, and tissue damage while modifying the underlying inflammatory processes that perpetuate clinical signs.

Acute bovine pulmonary emphysema and edema (ABPE), also known as atypical interstitial pneumonia or fog fever, represents a specific approved indication for flumethasone in cattle. This acute respiratory condition occurs when cattle are moved from dry pasture to lush forage, with conversion of the amino acid L-tryptophan to pneumotoxic metabolites causing severe pulmonary damage. Flumethasone administration as part of comprehensive treatment helps reduce pulmonary inflammation and improve respiratory function, though affected animals require additional supportive care and removal from offending pastures.

Allergic reactions and anaphylaxis in cattle benefit from the anti-inflammatory and membrane-stabilizing effects of flumethasone. While epinephrine remains the first-line treatment for acute anaphylactic reactions, flumethasone provides important adjunctive therapy that helps control the sustained inflammatory response following initial stabilization. Acute allergic conditions including urticaria, angioedema, and hypersensitivity reactions to insect stings, vaccines, or other antigens respond to corticosteroid therapy.

Equine applications of flumethasone include management of inflammatory musculoskeletal conditions, allergic reactions, and various inflammatory disorders. Joint inflammation, tendon and ligament injuries, and acute inflammatory responses benefit from the potent anti-inflammatory effects. Intra-articular administration provides direct delivery to inflamed joints while minimizing systemic exposure, though strict aseptic technique is essential to prevent joint infections.

Shock states and severe systemic inflammation represent additional applications where the cardiovascular stabilization and anti-inflammatory effects of flumethasone provide therapeutic benefit. The membrane-stabilizing effects help maintain vascular integrity and reduce capillary leakage during shock states. Treatment typically combines flumethasone with other supportive therapies including fluid administration and treatment of underlying causes.

Dosage protocols for flumethasone are based on approved label recommendations and established clinical experience, with typical doses for cattle ranging from 1.25 to 2.5 mg total dose per adult animal administered intravenously or intramuscularly for anti-inflammatory indications. Dose selection within this range depends on the severity of the condition being treated, desired intensity of anti-inflammatory effect, and individual patient factors. The potent nature of flumethasone means that relatively small absolute doses provide substantial therapeutic effects compared to less potent corticosteroids.

Acute bovine pulmonary emphysema treatment protocols typically employ flumethasone at doses of 1.25 to 2.5 mg administered intravenously or intramuscularly, often repeated at 24-hour intervals for 2 to 3 days depending on clinical response. Treatment is combined with removal of affected animals from offending pastures, provision of supplemental oxygen when available, and other supportive measures. Response to therapy should guide decisions regarding continued treatment.

Equine dosing for anti-inflammatory applications generally follows similar weight-based principles as cattle, with adjustments for horse body weights and specific condition severity. Intra-articular administration for joint inflammation employs lower doses delivered directly to affected joints, typically 1.25 mg or less per joint depending on joint size and degree of inflammation. Strict aseptic technique during intra-articular injection prevents introduction of bacteria that could cause septic arthritis.

Route of administration selection depends on clinical objectives and required speed of onset. Intravenous administration provides the most rapid onset of action for emergency situations requiring immediate effect. Intramuscular injection provides somewhat delayed absorption suitable for conditions where immediate peak effects are not essential. Intra-articular injection allows direct delivery to inflamed joints with minimal systemic exposure. Intralesional injection may be appropriate for localized inflammatory lesions.

Treatment duration should generally be limited to the shortest period necessary to achieve therapeutic objectives, as extended corticosteroid therapy produces cumulative adverse effects including hypothalamic-pituitary-adrenal suppression and immunosuppression. Most acute inflammatory conditions respond to single or short-course treatments lasting 1 to 3 days. Chronic conditions requiring longer treatment should be managed with the lowest effective dose and consideration of alternate-day therapy when appropriate.

Withdrawal time requirements for flumethasone must be strictly observed for food-producing animals. The approved meat withdrawal time for cattle in the United States is 7 days following treatment according to approved labeling. This withdrawal period must be documented and animals excluded from slaughter until the requirement is satisfied. Extra-label use, including higher doses, extended treatment, or non-approved routes, requires extended withdrawal determination through FARAD consultation. Flumethasone is not approved for use in lactating dairy cattle producing milk for human consumption.

Flumethasone produces the spectrum of adverse effects characteristic of potent glucocorticoids, with severity generally proportional to dose magnitude and treatment duration. The potent anti-inflammatory activity responsible for therapeutic benefits also underlies the side effects that may occur during or following treatment. Understanding these potential effects allows appropriate risk-benefit assessment and monitoring during flumethasone therapy.

Immunosuppressive effects represent the most significant clinical concern with flumethasone therapy, particularly for animals with concurrent or latent infectious diseases. Glucocorticoid-induced immunosuppression impairs multiple defense mechanisms including neutrophil chemotaxis and phagocytic function, lymphocyte proliferation and cytokine production, antibody responses, and cell-mediated immunity. Animals receiving flumethasone may show increased susceptibility to bacterial, viral, fungal, and parasitic infections, or may experience reactivation of latent infections. The immunosuppressive effects persist for some time after drug elimination, extending the period of increased infection susceptibility.

Metabolic effects include hyperglycemia resulting from enhanced gluconeogenesis and reduced peripheral glucose utilization. While often clinically inapparent with short-term treatment, these metabolic alterations can be significant in animals with pre-existing glucose intolerance or metabolic disease. Protein catabolism with negative nitrogen balance, muscle wasting, and impaired wound healing may occur with extended therapy. Lipid mobilization occurs with prolonged corticosteroid administration.

Gastrointestinal effects include increased risk of gastric and abomasal ulceration, particularly with prolonged treatment or concurrent NSAID use. Corticosteroids reduce protective prostaglandin production in the gastrointestinal mucosa and impair normal mucosal defense mechanisms. Clinical signs of gastrointestinal ulceration may be masked by the anti-inflammatory effects of the corticosteroid itself until significant bleeding or perforation occurs.

Reproductive effects include potential for parturition induction when flumethasone is administered during late pregnancy, with associated risks of retained placenta and compromised offspring viability. While parturition induction is not a primary indication for flumethasone, awareness of this potential effect guides appropriate use in pregnant animals. Early pregnancy administration may increase abortion risk.

Adrenal suppression occurs through negative feedback on the hypothalamic-pituitary-adrenal axis during exogenous corticosteroid administration. Extended or repeated treatment can suppress endogenous cortisol production, potentially leaving animals unable to mount appropriate stress responses. Recovery of normal adrenal function may require weeks following discontinuation of prolonged therapy.

Contraindications for flumethasone use in cattle and horses reflect the immunosuppressive and metabolic effects that may be harmful in certain clinical situations, as well as regulatory restrictions affecting food animal use. Active systemic infections represent a primary contraindication, as flumethasone-induced immunosuppression can allow uncontrolled pathogen proliferation and worsen infectious disease outcomes. Animals with bacterial, viral, fungal, or parasitic infections should not receive flumethasone unless concurrent antimicrobial therapy adequately addresses the infectious component and benefits clearly outweigh risks.

Systemic fungal infections present particular concern as contraindications for corticosteroid therapy. The immunosuppressive effects of flumethasone can permit dissemination of localized fungal infections or reactivation of latent fungal disease with serious or fatal consequences. Once disseminated fungal infections become established, they may be extremely difficult to control even after corticosteroid withdrawal.

Viral infections including bovine respiratory disease complex organisms may be worsened by corticosteroid-induced immunosuppression. While flumethasone may help control inflammatory aspects of respiratory disease, the impaired antiviral immunity can allow increased viral replication and tissue damage. The decision to use corticosteroids in respiratory disease requires careful consideration of the likely infectious agents involved and concurrent antimicrobial coverage.

Late pregnancy represents a contraindication when continuation of gestation is desired, as corticosteroid administration can induce parturition with risks of retained placenta and compromised offspring viability. This effect is dose-dependent and timing-dependent, with greater risks when administration occurs remote from natural parturition date.

Corneal ulceration contraindicates corticosteroid use, whether topical or systemic, due to risk of worsening infection, delayed healing, and corneal perforation. Any eye condition should be properly diagnosed before corticosteroid therapy is considered.

Animals with known hypersensitivity to flumethasone or other corticosteroids should not receive this medication. While true allergic reactions to corticosteroids are uncommon, prior adverse reactions contraindicate repeat exposure.

Lactating dairy cattle producing milk for human consumption should not receive flumethasone due to lack of approved milk withdrawal time. Animals intended for slaughter within the 7-day withdrawal period must not receive flumethasone treatment.

Drug interaction considerations for flumethasone involve both pharmacokinetic interactions affecting drug metabolism and pharmacodynamic interactions where combined effects alter safety or efficacy. Understanding these interactions guides appropriate concurrent medication selection and timing.

Non-steroidal anti-inflammatory drugs interact with flumethasone through complementary effects on the gastrointestinal mucosa that substantially increase ulcerogenic potential. Both drug classes independently reduce protective prostaglandin production, and concurrent use produces additive or synergistic increases in gastric ulceration risk. When both anti-inflammatory mechanisms are required, the lowest effective doses should be used for the shortest possible duration. Sequential rather than simultaneous use may partially reduce interaction risks. Gastroprotective concurrent therapy may be considered for animals receiving combined treatment.

Hepatic enzyme-inducing drugs including phenobarbital, phenytoin, and rifampin can accelerate flumethasone metabolism through enhanced cytochrome P450 activity. Animals receiving these medications concurrently may require higher flumethasone doses or more frequent administration to achieve desired therapeutic effects. Clinical response monitoring guides appropriate dose adjustment when enzyme inducers are present.

Aminoglycoside antibiotics may interact with corticosteroids through potential additive effects on neuromuscular function. While clinically significant interactions are uncommon at normal therapeutic doses, awareness of this potential supports appropriate monitoring when these drug classes are used concurrently.

Vaccine efficacy may be reduced by concurrent flumethasone administration due to immunosuppressive effects. Vaccination during or shortly after corticosteroid treatment may fail to produce adequate protective immunity. When possible, vaccination should be scheduled before corticosteroid therapy or delayed until immunosuppressive effects have resolved. Live vaccines present particular concerns as impaired immunity could potentially allow vaccine organism replication.

Insulin and glucose-regulating medications may require adjustment during flumethasone therapy due to corticosteroid-induced insulin resistance and hyperglycemia. While diabetes mellitus is uncommon in production livestock, any concurrent use of glucose-regulating agents requires attention to metabolic status.

Potassium-depleting diuretics used concurrently with flumethasone could potentially produce additive hypokalemia, though the minimal mineralocorticoid activity of flumethasone reduces this concern compared to corticosteroids with significant mineralocorticoid effects.

Human safety precautions during flumethasone handling emphasize avoiding exposure to concentrated drug products and preventing accidental self-injection. Personnel handling injectable corticosteroids should wear protective gloves and use careful technique to minimize exposure and prevent needlestick injuries. Accidental self-injection requires immediate medical attention, as systemic corticosteroid effects can result from parenteral exposure. Pregnant women should avoid handling flumethasone due to potential fetal effects from corticosteroid exposure. Individuals with known corticosteroid sensitivity should take particular care to avoid contact.

Food safety considerations require strict adherence to withdrawal time requirements for flumethasone use in cattle. The approved meat withdrawal period is 7 days following treatment according to label directions. Animals must be clearly identified and excluded from slaughter until withdrawal requirements are satisfied. Treatment records documenting animal identification, product used, dose, route, treatment date, and withdrawal expiration date support compliance verification. Extra-label use requires extended withdrawal determination through FARAD consultation. Flumethasone is not approved for lactating dairy cattle, effectively prohibiting use in animals producing milk for commercial sale.

Immunosuppression warnings emphasize the increased susceptibility to infectious diseases during and following flumethasone therapy. Treatment should not be initiated in animals with active infections unless concurrent antimicrobial therapy is provided. Treated animals should be monitored for emergence of secondary or opportunistic infections. Vaccination should be avoided during the period of immunosuppression, and animals previously vaccinated may show impaired responses if corticosteroid treatment becomes necessary shortly after vaccination.

Pregnancy warnings reflect the potential for flumethasone to induce parturition when administered during late pregnancy. Pregnancy status should be determined before initiating therapy in breeding-age females. When treatment of pregnant animals is necessary, the risks of premature parturition must be considered against therapeutic benefits.

Adrenal suppression warnings apply to animals receiving repeated or prolonged flumethasone therapy. Extended treatment suppresses endogenous cortisol production through negative feedback. Animals may require supplemental corticosteroid therapy during stressful events until adrenal function recovers. Gradual dose tapering may help prevent adrenal crisis when discontinuing prolonged therapy.

Laminitis risk should be considered when using flumethasone or any corticosteroid in horses or cattle, as these drugs have been associated with laminitis development in susceptible animals.

Storage requirements for flumethasone injectable solutions emphasize protection from light, temperature extremes, and physical damage that could compromise product sterility and stability. Products should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from freezing and excessive heat exposure. Light-sensitive formulations require storage in original cartons or other light-protective containers to prevent photodegradation. Proper storage ensures maintained potency throughout the product shelf life.

Multi-dose vial handling requires strict aseptic technique to maintain product sterility and prevent microbial contamination that could cause injection site infections or systemic illness in treated animals. Rubber stoppers should be disinfected with alcohol swabs before each needle entry. Sterile needles and syringes should be used for each dose withdrawal, never reusing needles that have contacted animals or other surfaces. Vials showing any evidence of contamination, particulate matter, color change, or turbidity should be discarded immediately. Open vials should be used within the timeframe specified by the manufacturer, typically 28 days or less after first entry.

Disposal of unused flumethasone products and empty containers must follow applicable pharmaceutical waste regulations. Partially used vials, expired product, and empty containers should not be disposed of in regular trash or poured into drains or water systems. Many jurisdictions classify pharmaceutical waste as requiring special handling procedures. Veterinary practices and farms should establish protocols for pharmaceutical waste management that comply with federal, state, and local environmental regulations. Sharps including used needles and syringes require disposal in approved sharps containers.

Species-specific considerations for flumethasone use focus on the approved indications in cattle and horses, with each species presenting unique physiological characteristics and management contexts that influence therapeutic applications. Cattle represent a primary target species for flumethasone applications including acute bovine pulmonary emphysema, inflammatory conditions, and allergic reactions. Individual variation in corticosteroid sensitivity exists within cattle populations, and dose adjustments may be appropriate for animals showing unusual sensitivity or resistance to standard doses.

Beef versus dairy cattle considerations primarily involve regulatory constraints rather than pharmacological breed differences. Dairy cattle producing milk for human consumption cannot receive flumethasone due to lack of approved milk withdrawal times. Beef cattle intended for slaughter must observe the 7-day meat withdrawal period. The different production contexts and marketing timelines of beef and dairy operations influence treatment decisions and withdrawal planning.

Breed size considerations affect absolute dosing when weight-based calculations are employed. Larger-framed breeds require proportionally higher absolute doses than smaller animals to achieve equivalent tissue concentrations. Accurate weight estimation or measurement supports appropriate dosing across diverse breed types. Individual body condition may also influence drug distribution and response.

Equine applications of flumethasone include anti-inflammatory therapy for musculoskeletal conditions, allergic reactions, and various inflammatory disorders. Horse breed differences in drug metabolism have not been extensively characterized for flumethasone specifically, though individual variation in corticosteroid sensitivity occurs. Draft breeds with substantially higher body weights than light horse breeds require appropriately scaled doses.

Age considerations apply across species, with young animals potentially showing enhanced sensitivity to corticosteroid effects and elderly animals possibly exhibiting altered drug metabolism. Growing animals receiving corticosteroid therapy may show temporary growth suppression. Production stage considerations include avoiding treatment during late pregnancy when continuation of gestation is desired, and attention to withdrawal requirements relative to marketing timelines for slaughter animals.

Dexamethasone represents the most commonly utilized alternative glucocorticoid in food animal veterinary practice, with extensive clinical experience, broad product availability, and established regulatory framework for approved uses. Dexamethasone exhibits potency approximately 1.5 to 2 times that of flumethasone and similar duration of action. The wide availability of dexamethasone formulations and extensive familiarity among practitioners often make it the corticosteroid of choice, with flumethasone serving as a useful alternative when specific product characteristics favor its selection.

Betamethasone provides another potent synthetic glucocorticoid option with similar anti-inflammatory potency to dexamethasone. This compound shares the fluorinated structure that provides high glucocorticoid activity with minimal mineralocorticoid effects. Betamethasone availability and approved indications vary by region, influencing its selection relative to dexamethasone and flumethasone.

Prednisolone and prednisone offer intermediate-potency glucocorticoid options with shorter duration of action compared to fluorinated corticosteroids. These compounds require higher doses to achieve equivalent anti-inflammatory effects compared to flumethasone, dexamethasone, or betamethasone. The shorter duration of action may be advantageous when more frequent dose adjustment flexibility is desired. Fewer products are approved for food animal use compared to potent fluorinated corticosteroids.

Isoflupredone acetate is specifically approved for cattle use and provides another potent glucocorticoid option with established withdrawal times. This compound is sometimes preferred for specific applications based on formulation characteristics and approved indications.

Methylprednisolone and triamcinolone provide additional glucocorticoid options occasionally used in food animal practice. These compounds offer varying potency and duration characteristics that may suit specific clinical situations. Product availability and approved species/indications influence selection among available corticosteroid options.

Hydrocortisone (cortisol) represents the natural glucocorticoid against which synthetic compounds are compared, with substantially lower potency than flumethasone and other synthetic corticosteroids. Hydrocortisone may be appropriate for physiologic replacement therapy or mild inflammatory conditions where potent glucocorticoid effects are not required.